Search

Innoviva Inc

Fechado

SetorSaúde

21.1 0.76

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.86

Máximo

21.23

Indicadores-chave

By Trading Economics

Rendimento

-270M

-83M

Vendas

22M

120M

P/E

Médio do Setor

4.891

57.366

EPS

0.59

Margem de lucro

-69.754

Funcionários

159

EBITDA

28M

267M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+93.39% upside

Dividendos

By Acuity

Próximos Ganhos

3 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-14M

1.5B

Abertura anterior

20.34

Fecho anterior

21.1

Sentimento de Notícias

By Acuity

50%

50%

167 / 340 Ranking em Healthcare

Innoviva Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de ago. de 2026, 21:02 UTC

Innoviva Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

21 de ago. de 2026, 19:46 UTC

Innoviva Inc's shares are higher during Friday's session, reflecting a modest increase since Thursday's close. No specific news was identified for the movement.

20 de ago. de 2026, 20:02 UTC

Shares of Innoviva Inc are declining amid broader market pressures following Walmart Inc's disappointing earnings report, raising concerns about consumer spending.

19 de ago. de 2026, 19:26 UTC

Innoviva Inc's shares are higher during Wednesday's session, maintaining strength above the 20-day moving average and near the upper end of its one-month range.

18 de ago. de 2026, 20:06 UTC

Innoviva Inc is trading higher, supported by strength in the Pharmaceuticals sub-sector. The stock has shown a steady rise since Monday's close.

14 de ago. de 2026, 19:56 UTC

Innoviva Inc shares are higher during Friday's session, recovering from earlier losses despite no specific news. Broader market sentiment is affected by declining U.S. retail sales.

13 de ago. de 2026, 19:41 UTC

Innoviva Inc shares are lower during Thursday's session, with no specific news identified. The stock remains below its 20-day moving average.

12 de ago. de 2026, 19:06 UTC

Event

Innoviva Inc's therapies are finalists for the 2026 Prix Galien USA Award, but shares are trading lower, remaining below Tuesday's close.

11 de ago. de 2026, 19:16 UTC

Innoviva Inc's shares are higher in Tuesday's session, reflecting a modest gain since Monday's close. The stock remains below its 20-day moving average.

10 de ago. de 2026, 19:16 UTC

News

Innoviva shares are higher despite mixed analyst ratings and a price target cut from Cantor Fitzgerald to $34.00. HC Wainwright maintains a $46.00 target.

7 de ago. de 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6 de ago. de 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5 de ago. de 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3 de ago. de 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31 de jul. de 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30 de jul. de 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29 de jul. de 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28 de jul. de 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27 de jul. de 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21 de jul. de 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20 de jul. de 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Comparação entre Pares

Variação de preço

Innoviva Inc Previsão

Preço-alvo

By TipRanks

93.39% parte superior

Previsão para 12 meses

Média 40.67 USD  93.39%

Máximo 46 USD

Mínimo 34 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Innoviva Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

167 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat